Breaking News

Pfizer, BioNTech COVID-19 Vax Candidate Successful in Phase III Interim Analysis

mRNA-based vaccine candidate BNT162b2 found to be more than 90% effective in preventing COVID-19.

By: Contract Pharma

Contract Pharma Staff

Pfizer and BioNTech’s mRNA-based vaccine candidate, BNT162b2 against SARS-CoV-2, has demonstrated efficacy against COVID-19 in participants without prior evidence of SARS-CoV-2 infection, based on interim efficacy analysis by an independent Data Monitoring Committee (DMC) from the Phase III trial. After discussion with the FDA, the companies recently elected to drop the 32-case interim analysis and conduct the first interim analysis at a minimum of 62 cases. Upon the conclusion of those discussions, the evaluable case count reached 94 and the DMC performed its first analysis on all cases.

The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a 2-dose schedule.

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters